Home Seattle Genetics: 3 Reasons Why I Like This Midcap Biotech
 

Keywords :   


Seattle Genetics: 3 Reasons Why I Like This Midcap Biotech

2015-09-30 20:28:30| Biotech - Topix.net

Adcetris is in the midst of three Phase 3 and four Phase 2 trials to test its viability in treating other cancers and lymphoma. In the world of small- and mid-cap biotech companies it's often times a feast or famine proposition.

Tags: this reasons seattle genetics

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
18.06Tnemec Elevates Coatings Education with Newly Appointed AMPP CIP Instructor
18.06Next MANAchat Series is Scheduled for the Week of August 5
18.06Ruben Harris joins Flexcon as VP of supply chain
18.06Joanna Gaines, KILZ Debut Magnolia Lakehouse Collection
18.06Advanced Polymer Coatings Launches TriFLEX for Rail Cars
18.06Potential Tropical Cyclone One Graphics
18.06Potential Tropical Cyclone One Forecast Discussion Number 4
18.06Potential Tropical Cyclone One Forecast Advisory Number 4
More »